GSK vs. JAZZ: GSK vs. Jazz Pharmaceuticals Stock Comparison
How do GSK (GSK) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
GSK (GSK) and Jazz Pharmaceuticals (JAZZ) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Jazz Pharmaceuticals (JAZZ) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | GSK | JAZZ |
|---|---|---|
| Name | GSK plc ADR | Jazz Pharmaceuticals plc |
| Country/Region | United Kingdom | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 100.88 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | March 28, 1980 | June 1, 2007 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| Total Return (1Y) | 13.73% | 84.44% |
| Total Return (3Y, Annualized) | 18.65% | 27.57% |
| Total Return (5Y, Annualized) | 7.97% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 26.25% | 38.74% |
| Beta (5Y) | 0.31 | 0.33 |
| Max Drawdown (5Y) | -37.63% | -42.03% |
| Avg. Volume (3M) | 4.05M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.36 | 2.07 |
| Sortino Ratio (1Y) | 0.56 | 4.14 |
Profitability
ROE (TTM)
GSK (GSK) at 28.27% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for GSK.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.27%
- Max
- 109.18%
- GSK
- 28.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
GSK (GSK) at 12.97% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.97%
- Max
- 18.05%
- GSK
- 12.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both GSK (GSK) at 32.14% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.14%
- Max
- 83.12%
- GSK
- 32.14%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| ROE (TTM) | 28.27% | 5.05% |
| ROA (TTM) | 9.24% | 6.92% |
| Net Margin (TTM) | 12.97% | 4.37% |
| Operating Margin (TTM) | 32.14% | 30.17% |
| Gross Margin (TTM) | 73.79% | 91.10% |
Growth
Revenue Growth
Both GSK (GSK) at 4.11% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
GSK (GSK) at 123.15% sits in the top EPS growth quartile, while Jazz Pharmaceuticals (JAZZ) at -167.51% is in the bottom quartile, showing a clear gap in earnings momentum.
Growth Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 4.11% | 4.88% |
| Revenue Growth (3Y CAGR) | 3.66% | 5.26% |
| EPS Growth (YoY) | 123.15% | -167.51% |
| EPS Growth (3Y CAGR) | -27.63% | -- |
Financial Strength
Current Ratio (MRQ)
Both GSK (GSK) at 0.86 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GSK
- 0.86
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Both GSK (GSK) at 1.30 and Jazz Pharmaceuticals (JAZZ) at 1.35 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.30
- Max
- 1.42
- GSK
- 1.30
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 1.82 |
| Debt / Equity (MRQ) | 1.30 | 1.35 |
| Net Debt / EBITDA | 1.88 | 1.39 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.57%
- GSK
- 1.57%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
63.33%
- GSK
- 63.33%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 1.57% | 0.00% |
| Dividend Payout Ratio (TTM) | 63.33% | 0.00% |
Valuation
P/E Ratio (TTM)
GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.54
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- GSK
- 17.54
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.01
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- GSK
- 3.01
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both GSK (GSK) at 4.02 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.02
- Max
- 13.53
- Q3
- 6.54
- GSK
- 4.02
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GSK | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 17.54 | 69.46 |
| P/S Ratio (TTM) | 3.01 | 3.19 |
| P/B Ratio (MRQ) | 4.02 | 3.59 |
| Free Cash Flow Yield (TTM) | 5.28% | 11.16% |